Literature DB >> 22941572

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.

Laura A Petrillo1, Denise M Wolf2, Ann M Kapoun3, Nicholas J Wang4, Andrea Barczak5, Yuanyuan Xiao5, Hasan Korkaya6, Frederick Baehner7, John Lewicki3, Max Wicha6, John W Park2, Paul T Spellman4, Joe W Gray4, Laura Van't Veer2, Laura J Esserman8.   

Abstract

Though xenografts are used extensively for drug development in breast cancer, how well xenografts reflect the breadth of primary breast tumor subtypes has not been well characterized. Moreover, few studies have compared the gene expression of xenograft tumors to the primary tumors from which they were derived. Here we investigate whether the ability of human breast tumors (n = 20) to create xenografts in immune-deficient mice is associated with breast cancer immunohistochemical (IHC) and intrinsic subtype. We also characterize how precisely the gene expression of xenografts reprises that of parent breast tumors, using hierarchical clustering and other correlation-based techniques applied to Agilent 44K gene expression data from 16 samples including four matched primary tumor-xenograft pairs. Of the breast tumors studied, 25 % (5/20) generated xenografts. Receptor and intrinsic subtype were significant predictors of xenograft success, with all (4/4) triple-negative (TN) tumors and no (0/12) HR+Her2- tumors forming xenografts (P = 0.0005). Tumor cell expression of ALDH1, a stem cell marker, trended toward successful engraftment (P = 0.14), though CDK5/6, a basal marker, did not. Though hierarchical clustering across the 500 most variable genes segregated human breast tumors from xenograft tumors, when clustering was performed over the PAM50 gene set the primary tumor-xenograft pairs clustered together, with all IHC subtypes clustered in distinct groups. Greater similarity between primary tumor-xenograft pairs relative to random pairings was confirmed by calculation of the within-pair between-pair scatter ratio (WPBPSR) distribution (P = 0.0269), though there was a shift in the xenografts toward more aggressive features including higher proliferation scores relative to the primary. Triple-negative breast tumors demonstrate superior ability to create xenografts compared to HR+ tumors, which may reflect higher proliferation or relatively stroma-independent growth of this subtype. Xenograft tumors' gene expression faithfully resembles that of their parent tumors, yet also demonstrates a shift toward more aggressive molecular features.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941572      PMCID: PMC3873871          DOI: 10.1007/s10549-012-2226-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias.

Authors:  B M Bolstad; R A Irizarry; M Astrand; T P Speed
Journal:  Bioinformatics       Date:  2003-01-22       Impact factor: 6.937

Review 2.  Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.

Authors:  Mark Pegram; Debbie Ngo
Journal:  Adv Drug Deliv Rev       Date:  2006-05-23       Impact factor: 15.470

3.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.

Authors:  Britta Weigelt; Zhiyuan Hu; Xiaping He; Chad Livasy; Lisa A Carey; Matthew G Ewend; Annuska M Glas; Charles M Perou; Laura J Van't Veer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

4.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

5.  Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy.

Authors:  B C Giovanella; J S Stehlin; L J Williams; S S Lee; R C Shepard
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

6.  A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Authors:  Elisabetta Marangoni; Anne Vincent-Salomon; Nathalie Auger; Armelle Degeorges; Franck Assayag; Patricia de Cremoux; Ludmilla de Plater; Charlotte Guyader; Gonzague De Pinieux; Jean-Gabriel Judde; Magali Rebucci; Carine Tran-Perennou; Xavier Sastre-Garau; Brigitte Sigal-Zafrani; Olivier Delattre; Véronique Diéras; Marie-France Poupon
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

Review 7.  Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Growth and metastasis of human breast carcinomas with Matrigel in athymic mice.

Authors:  R R Mehta; J M Graves; G D Hart; A Shilkaitis; T K Das Gupta
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

Review 10.  The response to chemotherapy of a variety of human tumour xenografts.

Authors:  G G Steel; V D Courtenay; M J Peckham
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

View more
  21 in total

Review 1.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

Review 2.  ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.

Authors:  Sarah K Herzog; Suzanne A W Fuqua
Journal:  Br J Cancer       Date:  2021-10-07       Impact factor: 9.075

3.  A quantitative proteomics analysis of MCF7 breast cancer stem and progenitor cell populations.

Authors:  Song Nie; Sean P McDermott; Yadwinder Deol; Zhijing Tan; Max S Wicha; David M Lubman
Journal:  Proteomics       Date:  2015-10-07       Impact factor: 3.984

4.  Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Authors:  Pierre-Emmanuel Colombo; Stanislas du Manoir; Béatrice Orsett; Rui Bras-Gonçalves; Mario B Lambros; Alan MacKay; Tien-Tuan Nguyen; Florence Boissière; Didier Pourquier; Frédéric Bibeau; Jorge S Reis-Filho; Charles Theillet
Journal:  Oncotarget       Date:  2015-09-29

Review 5.  Personalising pancreas cancer treatment: When tissue is the issue.

Authors:  Katrin M Sjoquist; Venessa T Chin; Lorraine A Chantrill; Chelsie O'Connor; Chris Hemmings; David K Chang; Angela Chou; Marina Pajic; Amber L Johns; Adnan M Nagrial; Andrew V Biankin; Desmond Yip
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 6.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Authors:  Lacey E Dobrolecki; Susie D Airhart; Denis G Alferez; Samuel Aparicio; Fariba Behbod; Mohamed Bentires-Alj; Cathrin Brisken; Carol J Bult; Shirong Cai; Robert B Clarke; Heidi Dowst; Matthew J Ellis; Eva Gonzalez-Suarez; Richard D Iggo; Peter Kabos; Shunqiang Li; Geoffrey J Lindeman; Elisabetta Marangoni; Aaron McCoy; Funda Meric-Bernstam; Helen Piwnica-Worms; Marie-France Poupon; Jorge Reis-Filho; Carol A Sartorius; Valentina Scabia; George Sflomos; Yizheng Tu; François Vaillant; Jane E Visvader; Alana Welm; Max S Wicha; Michael T Lewis
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

Review 7.  Patient-derived xenograft models of breast cancer and their predictive power.

Authors:  James R Whittle; Michael T Lewis; Geoffrey J Lindeman; Jane E Visvader
Journal:  Breast Cancer Res       Date:  2015-02-10       Impact factor: 6.466

Review 8.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Authors:  Melissa D Landis; Brian D Lehmann; Jennifer A Pietenpol; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466

9.  Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.

Authors:  Haiyu Zhang; Adam L Cohen; Sujatha Krishnakumar; Irene L Wapnir; Selvaraju Veeriah; Glenn Deng; Marc A Coram; Caroline M Piskun; Teri A Longacre; Michael Herrler; Daniel O Frimannsson; Melinda L Telli; Frederick M Dirbas; A C Matin; Shanaz H Dairkee; Banafshe Larijani; Gennadi V Glinsky; Andrea H Bild; Stefanie S Jeffrey
Journal:  Breast Cancer Res       Date:  2014-04-07       Impact factor: 6.466

10.  Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Authors:  David Vallerand; Gérald Massonnet; Fatima Kébir; David Gentien; Zofia Maciorowski; Pierre De la Grange; Brigitte Sigal-Zafrani; Marion Richardson; Sandrine Humbert; Aurélie Thuleau; Franck Assayag; Ludmilla de Plater; André Nicolas; Suzy Scholl; Elisabetta Marangoni; Stefan Weigand; Sergio Roman-Roman; Ariel Savina; Didier Decaudin
Journal:  PLoS One       Date:  2016-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.